BUFFALO, N.Y., May 14, 2013 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) and Incuron, LLC, a joint venture between the Company and Bioprocess Capital Ventures, today announced the receipt of a Notice of Allowance from the U.S. Patent and Trademark Office for the Curaxin U.S. Patent Application Number 12/993,018, titled "Inducing Cell Death by Inhibiting Adaptive Heat Shock Response." This patent was recently issued in the Russian Federation, as well. Curaxins include CBL0137, which is a carbazole and CBL0102, which is a quinacrine.
The European Patent Office also issued a Notice of Grant for European Patent Number EP2356093, titled "Carbazole Compounds and Therapeutic Uses of the Compounds." This patent was also allowed in New Zealand, South Africa, and Kazhakstan.
In addition, the Australian patent authority had previously granted patent Number 2005267117 titled, "Inhibition of NF-kappaB" for carbazole compounds.
Andrei Gudkov, Ph.D., D.Sci., Chief Scientific Officer of Cleveland BioLabs, noted, "Inhibition of adaptive heat shock response and NF-kappaB have long been recognized as attractive targets for oncology therapeutics. In fact, many known efficacious drugs being used today focus on these targets independently, which underscores the importance of these patents. The uniqueness of our Curaxin drug candidates CBL0137 and CBL0102 is that they simultaneously affect both of these pathways and others through interaction with an upstream regulator. As such, we hope our Curaxins will provide a clinically relevant improvement to existing therapies."
CBLI and Incuron recently announced the receipt of a Notice of Allowance from the U.S. Food and Drug Administration (FDA) for an Investigational New Drug (IND) application for CBL0137.
About Cleveland BioLabs, Inc.
Cleveland BioLabs, Inc. is a clinical-stage biotechnology company leveraging deep mechanistic understanding of the cell death process, apoptosis, to develop a robust pipeline of compounds primarily focused on oncology applications and mitigation of radiation injury. The Company's lead compound is being developed as both a radiation countermeasure and a cancer treatment. The Company has two operating subsidiaries, Incuron, LLC, and Panacela Labs, Inc., and strategic relationships with the Cleveland Clinic, Roswell Park Cancer Institute, the Children's Cancer Institute Australia and the Armed Forces Radiobiology Research Institute. To learn more about Cleveland BioLabs, Inc., please visit the Company's website at http://www.cbiolabs.com.
About Incuron, LLC
Incuron, LLC is a Russian Federation based joint venture founded in 2010 between Russian Closed Mutual Venture Fund "Bioprocess Capital Ventures," and Cleveland BioLabs. Incuron is developing CBL0102 and CBL0137 for oncology and orphan indications. To learn more about Incuron, LLC, please visit the company's website at http://www.incuron.com/.
This press release contains certain forward-looking information about Cleveland BioLabs that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)," "feel(s)," "believe(s)," "will," "may," "anticipate(s)" and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding our ability to successfully obtain regulatory approval for our therapeutic product candidates; statements regarding our ability to successfully develop and commercialize our therapeutic products; our ability to expand our long-term business opportunities; the conduct and results of our various clinical trials; and future performance. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements.
These factors include, among others, the Company's inability to obtain regulatory approval in a timely manner or at all; the Company's failure to develop new products; the Company's collaborative relationships and the financial risks related thereto; the risks inherent in the early stages of drug development and in conducting clinical trials. Some of these factors could cause future results to materially differ from the recent results or those projected in forward-looking statements. See also the "Risk Factors" and "Forward-Looking Statements" described in the Company's periodic filings with the Securities and Exchange Commission.
Contact:
Rachel Levine, Vice President, Investor Relations
Cleveland BioLabs, Inc.
T: (646) 284-9439
E: rlevine@cbiolabs.com